The Evolution of Lupus Nephritis Treatment; from Conventional to Targeted and Biologics Therapy
| Dublin Core | PKP Metadata Items | Metadata for this Document | |
| 1. | Title | Title of document | The Evolution of Lupus Nephritis Treatment; from Conventional to Targeted and Biologics Therapy |
| 2. | Creator | Author's name, affiliation, country | Warot Piriyasanguanpong; Allergy and Rheumatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,; Thailand |
| 2. | Creator | Author's name, affiliation, country | Siriporn Juthong; Allergy and Rheumatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,; Thailand |
| 2. | Creator | Author's name, affiliation, country | Duangkamol Aiewruengsurat; Allergy and Rheumatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,; Thailand |
| 2. | Creator | Author's name, affiliation, country | Porntip Intapiboon; Allergy and Rheumatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,; Thailand |
| 3. | Subject | Discipline(s) | |
| 3. | Subject | Keyword(s) | biologic therapy; lupus nephritis; systemic lupus erythematosus; targeted therapy |
| 4. | Description | Abstract | Lupus nephritis (LN) is a common and severe organ manifestation in patients with systemic lupus erythematosus (SLE). LN can present alone or with accompanying extra-renal symptoms. The prevalence and severity vary depending on ethnicity, genetics, and environmental exposure. However, the presence of LN in SLE is a surrogate indicator of disease severity, frequent relapse, increased chronic kidney disease (CKD), and mortality risks. The current conventional standard treatments for LN include corticosteroids, immunosuppressive drugs, and antimalarial drugs. Despite an optimal standard treatment regimen, the outcomes of renal remission, decreased CKD risk, and quality of life are unsatisfactory. In addition, corticosteroid and immunosuppressive drug toxicity are of primary concern. Thus, two dozen promising biological and targeted drugs are being studied in the LN treatment pipeline to improve renal outcomes and mitigate the side effects of conventional therapy. This article aims to review the pathogenesis of LN, summarise the current conventional strategy, and highlight the candidate novel drugs in LN included in Phase II and III clinical trials. These biologics, or targeted therapies, are hoped to facilitate the advancement of the LN treatment paradigm in the era of precision medicine. |
| 5. | Publisher | Organizing agency, location | Faculty of Medicine, Prince of Songkla University |
| 6. | Contributor | Sponsor(s) | |
| 7. | Date | (YYYY-MM-DD) | 2025-03-13 |
| 8. | Type | Status & genre | Peer-reviewed Article |
| 8. | Type | Type | |
| 9. | Format | File format | |
| 10. | Identifier | Uniform Resource Identifier | https://www.jhsmr.org/index.php/jhsmr/article/view/1125 |
| 10. | Identifier | Digital Object Identifier (DOI) | http://dx.doi.org/10.31584/jhsmr.20241125 |
| 11. | Source | Title; vol., no. (year) | Journal of Health Science and Medical Research; Vol 43, No 3 (2025): May-Jun |
| 12. | Language | English=en | en |
| 13. | Relation | Supp. Files | |
| 14. | Coverage | Geo-spatial location, chronological period, research sample (gender, age, etc.) | |
| 15. | Rights | Copyright and permissions |
Copyright (c) 2024 Journal of Health Science and Medical Research
 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |